Incyte (NASDAQ:INCY) Given New $65.00 Price Target at Morgan Stanley
Incyte (NASDAQ:INCY – Get Free Report) had its target price dropped by equities research analysts at Morgan Stanley from $69.00 to $65.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential […]
Incyte (NASDAQ:INCY – Get Free Report) had its target price dropped by equities research analysts at Morgan Stanley from $69.00 to $65.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential […]
